Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities Nicholas WillumsenLouise B. ThomsenMorten A. Karsdal Review 11 October 2017 Pages: 1 - 12
The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer Mohammad W. KhanAbdulrahman SaadallaKhashayarsha Khazaie Original Article 05 September 2017 Pages: 13 - 23
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies Paulina NowakowskaAnnette RomanskiTorsten Tonn Original Article 06 September 2017 Pages: 25 - 38
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease Stefan DiemOmar Hasan AliLukas Flatz Original Article 11 September 2017 Pages: 39 - 45
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression Jonathan P. O. HebbAdriane R. MosleyDean W. Felsher Original Article 13 September 2017 Pages: 47 - 60
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report Jumpei KashimaYusuke OkumaKazuro Chiba Original Article 14 September 2017 Pages: 61 - 65
Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat model Kerem TekeNil GuzelOzdal Dillioglugil Original Article 15 September 2017 Pages: 67 - 77
HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients Jiajun WangLi LiuJianming Guo Original Article 16 September 2017 Pages: 79 - 87
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer Jitka FucikovaMichal PodrazilJirina Bartunkova Original Article 25 September 2017 Pages: 89 - 100
Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth Nikolai N. BelyaevNurshat AbdollaRaikhan Tleulieva Original Article 27 September 2017 Pages: 101 - 111
Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules Atsunari KawashimaTakayuki KanazawaHisashi Wada Original Article 03 October 2017 Pages: 113 - 125
Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study Daniel FranzenKarin SchadMalcolm Kohler Original Article 05 October 2017 Pages: 127 - 134
Safety of shortened infusion times for combined ipilimumab and nivolumab Maximilian GassenmaierHans-Peter LippAndrea Forschner Original Article 07 October 2017 Pages: 135 - 140
Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy Tímea BalatoniAnita MohosAndrea Ladányi Original Article 07 October 2017 Pages: 141 - 151
2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece Pinelopi SamaraAthanasios KotsakisConstantin N. Baxevanis Meeting Report 01 December 2017 Pages: 153 - 159